Editas Medicine (EDIT)

• Market cap: $158M
• 1 day: -6.80%
• 5 days: 54.84%
• 1 month: 58.68%
• 3 months: -18.99%
• 6 months: -52.94%
• Year to date: 46.56%
• 1 year: -76.03%
• 5 years: -92.24%
• 10 years: -89.45%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Employees: 226

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

2% more call options, than puts

Call options by funds: $396K | Put options by funds: $388K

2% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 58

6.14% less ownership

Funds ownership: 67.79% [Q3] → 61.65% (-6.14%) [Q4]

14% less funds holding

Funds holding: 227 [Q3] → 196 (-31) [Q4]

42% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 57

66% less capital invested

Capital invested by funds: $190M [Q3] → $65.3M (-$125M) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 56% upside
• Avg. target: $4.50 134% upside
• High target: $8 317% upside

6 analyst ratings

• positive: 2 33%
• neutral: 4 67%
• negative: 0 0%

Evercore ISI Group Liisa Bayko 71% 1-year accuracy 10 / 14 met price target	160% upside $5	Outperform Maintained	16 Dec 2024
RBC Capital Luca Issi 21% 1-year accuracy 12 / 56 met price target	108% upside $4	Sector Perform Maintained	13 Dec 2024
Barclays Gena Wang 17% 1-year accuracy 5 / 29 met price target	56% upside $3	Equal-Weight Maintained	13 Dec 2024
Baird Joel Beatty 53% 1-year accuracy 21 / 40 met price target	317% upside $8	Outperform Maintained	13 Dec 2024
Stifel Dae Gon Ha 42% 1-year accuracy 5 / 12 met price target	56% upside $3	Hold Downgraded	13 Dec 2024